Crossref
Encorafenib and binimetinib as a new regimen for BRAF mutant non-small cell lung cancer
AME Clinical Trials Review · 2023
DOI: 10.21037/actr-23-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2023. Verfasst von Taichiro Goto.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Goto, T. (2023). Encorafenib and binimetinib as a new regimen for BRAF mutant non-small cell lung cancer. AME Clinical Trials Review. https://doi.org/10.21037/actr-23-24
Vancouver
Goto T. Encorafenib and binimetinib as a new regimen for BRAF mutant non-small cell lung cancer. AME Clinical Trials Review. 2023. doi:10.21037/actr-23-24
BibTeX
@article{Goto2023,
author = {Goto, Taichiro},
title = {Encorafenib and binimetinib as a new regimen for BRAF mutant non-small cell lung cancer},
journal = {AME Clinical Trials Review},
year = {2023},
doi = {10.21037/actr-23-24}
}
EUVIMED